MASLD 2 - Medxy AI

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates Gastroenterology news Specialties

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Clinical Updates Diabetes & Endocrinology news Specialties

Weekend Warrior Exercise Patterns: Comparable Cardiometabolic Protection to Regular Activity in Diabetes and MASLD

By MedXY 07/31/2025

Accumulating 150 minutes of moderate-to-vigorous physical activity weekly, either as a 'weekend warrior' or in regular sessions, significantly reduces mortality and cardiometabolic risk in adults with diabetes and MASLD.

Medical News news Oncology Specialties

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY 07/31/2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.